The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $343.43

Today's change-7.89 -2.25%
Updated March 31 4:15 PM -4GMT. Delayed by at least 15 minutes.
 

Ishares Nasdaq Biotechnology

Nasdaq: IBB
Last

(U.S.) $343.43

Today's change-7.89 -2.25%
Updated March 31 4:15 PM -4GMT. Delayed by at least 15 minutes.

Ishares Nasdaq Biotechnology crosses below 20-day moving average

Ishares Nasdaq Biotechnology closed sharply lower Tuesday, dropping (U.S.)$7.89 or 2.25% to (U.S.)$343.43 and crossing below its 20-day moving average. Shares have lost 3.52% over the last five days, but have gained 13.21% over the last year to date. This security has outperformed the S&P 500 by 34.83% during the last year.

Key company metrics

  • Open(U.S.) $349.50
  • Previous close(U.S.) $351.32
  • High(U.S.) $349.81
  • Low(U.S.) $343.43
  • Bid / Ask(U.S.) $341.59 / (U.S.) $344.76
  • YTD % change+13.21%
  • Volume1,985,282
  • Average volume (10-day)2,877,892
  • Average volume (1-month)2,035,495
  • Average volume (3-month)1,661,922
  • 52-week range(U.S.) $207.48 to (U.S.) $374.97
  • Beta0.90
  • Trailing P/E6.23×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.13%
  • Trailing EPS(U.S.) $55.09
Updated March 31 4:15 PM -4GMT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q4/2014Q2/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Mar 31, 201403/31/2014Sep 30, 201309/30/2013Mar 31, 201303/31/2013
Revenue21985
Total other revenue--------
Total revenue21985
Gross profit--------
Total cost of revenue--------
Total operating expense121185
Selling / general / administrative121185
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income9-20-1
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax718446878259
Income after tax718446878259
Income tax, total0000
Net income718446878259
Total adjustments to net income--------
Net income before extra. items718446878259
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items718446878259
Inc. avail. to common incl. extra. items718446878259
Diluted net income718446878259
Dilution adjustment--0----
Diluted weighted average shares20231915
Diluted EPS excluding extraordinary itemsvalue per share36.0619.0345.6216.76
Dividends per sharevalue per share0.450.000.070.10
Diluted normalized EPSvalue per share36.0619.0345.6216.76